A - Utang jangka cendhak marang modal Agilent Technologies

Logo grafis Agilent (A)

The history of the short interest ratio confirms the resilience of Agilent Technologies (A), which relies on a global installed base of instruments and high-margin services. The value of 0.01 serves as a baseline indicator of financial maturity amid expectations for a recovery in biotech demand, which the market currently prices in. Dominance in biopharma and the growth of cancer diagnostics ensure stability through recurring customer payments.

Utang jangka cendhak marang ekuitas: Agilent Corp (A) kanggo 04.07.2022 - 30.10.2026
Produk mawa merek agilent.com

Agilent Technologies (A) is scaling the production of laboratory systems amid volatile demand from the biotech sector. This chart of the ratio between short-term liabilities and equity captures the share of obligations with maturities exceeding one year, determining the company's financial leverage. The current value of 0.01 allows for a real-time assessment of the business's dependence on borrowed capital under macroeconomic pressure from China. An increase in this indicator may enhance returns, but it raises the risk of asset drawdowns if client capital expenditures decline.

Pesaing utama

Utang jangka cendhak marang ekuitas Quest (DGX)|Illumina Platform - Rasio utang jangka cendhak marang modal|Utang jangka cendhak marang modal EXAS (Exact Sciences)|Utang jangka cendhak marang modal revvity.com RVTY|BIO - Utang jangka cendhak marang ekuitas|NNNN: Utang jangka cendhak marang ekuitas|SHC (Sterigenics) - Rasio utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang modal QuidelOrtho Inc. (QDEL)|Utang jangka cendhak marang ekuitas OPKO Health, Inc.|CareDx Corp (CDNA) - Koefisien utang jangka cendhak marang modal|Utang jangka cendhak marang modal MRVI|Koefisien utang jangka cendhak marang modal Fulgent Genetics Inc|Utang jangka cendhak marang ekuitas Fluidigm LAB|Koefisien utang jangka cendhak marang modal Cytek Corp (CTKB)|OraSure Technologies - Utang jangka cendhak marang modal|XGN - Utang jangka cendhak marang modal|MDXH: Utang jangka cendhak marang modal|Tanggungan utang jangka cendhak marang ekuitas Lucid Diagnostics, Inc. LUCD|PRE (Prenetics Global Limited) - Utang jangka cendhak marang modal|Insight Molecular (IMDX) - Koefisien utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Trinity Biotech plc (TRIB)|Utang jangka cendhak marang ekuitas PRPH (prophaselabs.com)|Utang jangka cendhak marang modal AIMD (Ainos)|Co-Diagnostics Inc (CODX) - Kewajiban jangka cendhak marang modal|HSCS - Utang jangka cendhak marang ekuitas|BMRA (Biomerica Inc) - Rasio utang jangka cendhak marang modal|CDIO (cardiodiagnosticsinc.com) - Rasio utang jangka cendhak marang ekuitas|VRAX: Rasio silihan jangka cendhak marang modal|Rasio utang jangka cendhak marang ekuitas BJDX|AWH: Rasio tanggungan utang jangka cendhak marang modal|Rasio utang jangka cendhak marang ekuitas AXDX (Accelerate Diagnostics, Inc)|Rasio silihan jangka cendhak marang modal CNTG|Utang jangka cendhak marang modal ENZ (Enzo Biochem)|Fresh2 Group Ltd (FRES) - Kewajiban jangka cendhak marang modal|GTG Labs - Utang jangka cendhak marang modal|23andMe Holding Co (ME) - Rasio utang jangka cendhak marang ekuitas|PMD: Utang jangka cendhak marang modal